According to Syqe Medical, the company has received regulatory approval from the Israeli Ministry of Health to launch its metered-dose cannabis inhaler in Israel for the treatment of pain. The inhaler, which was previously available only for hospital use, will now be available to licensed patients. In 2016, the company announced that Teva would distribute the plant-based cartridge inhaler to patients in Israel once approved.
Syqe Medical Founder and CEO Perry Davidson commented, “80% of cannabis patients inhale the plant. For too long, physicians who wish to treat these patients have been without the most basic clinical knowledge on dosing, efficacy and adverse events of cannabis. For eight years Syqe has been developing proprietary technologies for the administration of raw plants, and through our clinical trials we were able to determine the recommended dosage of inhaled cannabis down to the microgram. This launch marks the beginning of a new chapter in pain treatment, one in which physicians can confidently prescribe precise dosages of cannabis, and patients can reap the rewards, effectively and responsibly.”
Read the Syqe Medical press release.
